HDAC inhibitors such as romidepsin and vorinostat, used for the treatment of CTCL, have been reported to exhibit neuroprotective actions, either through the suppression of pro-apoptotic factors or through the release of pro-inflammatory factors of activated microglia [28,29]. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.